James Brumley
James Brumley (RSS)
InvestorPlace Contributor

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He's now primarily a freelance writer, tapping more than a decade's worth of broad experience to help investors get more out of the market.

Read complete bio
Recent Articles

A Q2 Report Card for 3D Printing Stocks

Aug. 14, 2014, 2:19 pm EDT – The second-quarter results from 3D printing stocks has widened the gap between the leaders and laggards. More 

Yes, It Really Is Time to Buy Gold Mining Stocks Like GDX and GDXJ

Aug. 14, 2014, 10:08 am EDT – After a painful drubbing in 2012 and 2013, gold prices show a glimmer of hope, and that's great news for gold mining stocks. More 

The Drop in iPad Sales Isn’t a Problem for Apple Stock

Aug. 13, 2014, 5:50 am EDT – Two rough quarters for iPad sales have some Apple stock owners sweating, but it's not a reason to steer clear of AAPL. More 

JCPenney Earnings – What to Know Before Thursday’s Report

Aug. 12, 2014, 8:16 am EDT – The JCPenney earnings update for Q2 is going to be a pivotal, make-or-break report. Here's what anyone interested in JCP stock needs to know. More 

For-Profit Colleges Have Little Blood Left to Give

Aug. 11, 2014, 2:33 pm EDT – Corinthian Colleges, ITT Educational Services, and other for-profit colleges look like a lost cause in their current state. More 

5 Buy-and-Hold-Forever Dividend Stocks

Aug. 8, 2014, 9:15 am EDT – The market's recent pullback has cranked up yields, and income investors may want to go shopping for dividend stocks. Here are five worth a look. More 

Big Data Gets Personal, Moving Past the Point of No Return

Aug. 7, 2014, 10:47 am EDT – Wal-Mart is the last of the major retailers to use big data to personalize its online sales pitch, proving that the practice is the new norm. More 

EBAY Stock Further Blurs the Line Between Tech and Financials

Aug. 6, 2014, 9:46 am EDT – Anyone who owns or may soon own EBAY stock may be wondering what's at stake for the company. Here's some food for thought. More 

Should AGN Just Take the Offer From Bill Ackman and VRX?

Aug. 5, 2014, 3:03 pm EDT – Bill Ackman and Valeant Pharmaceuticals have teamed up to acquire Allergan, but the saga isn't as simple as it seems. Here's the deal on AGN. More 

4 Biotech Stocks to Buy

Aug. 4, 2014, 11:35 am EDT – If this August is like most Augusts, the overall market isn't going to perform well for the next few weeks; biotech stocks may be the only worthwhile stocks to buy More